A Delphi Consensus Document on the Use of Single-Inhaler Fixed-Dose Triple Therapies in COPD Patients

References

• MiravitllesM, Soler-CatalunaJJ, CalleM, et al. Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017. Pharmacological treatment of stable phase. Arch Bronconeumol. 2017;53(6):324–335. doi:10.1016/j.arbres.2017.03.01828477954
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease - 2019 Report; 2019 Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.5-FINAL-04Nov2018_WMS.pdf. Accessed 2019
   Google Scholar
• VanfleterenL, FabbriLM, PapiA, PetruzzelliS, CelliB. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. Int J Chron Obstruct Pulmon Dis. 2018;13:3971–3981. doi:10.2147/COPD.S18597530587953
   PubMed Web of Science ®Google Scholar
• LipsonDA, BarnhartF, BrealeyN, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa171390129668352
   PubMed Web of Science ®Google Scholar
• PapiA, VestboJ, FabbriL, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084. doi:10.1016/S0140-6736(18)30206-X29429593
   PubMed Web of Science ®Google Scholar
• VestboJ, PapiA, CorradiM, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389(10082):1919–1929. doi:10.1016/S0140-6736(17)30188-528385353
   PubMed Web of Science ®Google Scholar
• de VilliersMR, de VilliersPJ, KentAP. The Delphi technique in health sciences education research. Med Teach. 2005;27(7):639–643. doi:10.1080/1361126050006994716332558
   PubMed Web of Science ®Google Scholar
• GaduzoS, McGovernV, RobertsJ, ScullionJ, SinghD. When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals. Int J Chron Obstruct Pulmon Dis. 2019;14:391–401. doi:10.2147/COPD.S17390130863039
   PubMed Web of Science ®Google Scholar
• WorthH, BuhlR, CrieeCP, KardosP, LossiNS, VogelmeierCF. GOLD 2017 treatment pathways in ‘real life’: an analysis of the DACCORD observational study. Respir Med. 2017;131:77–84. doi:10.1016/j.rmed.2017.08.00828947047
   PubMed Web of Science ®Google Scholar
• ZhengY, ZhuJ, LiuY, et al. Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis. BMJ. 2018;363.
   PubMedGoogle Scholar
• Lopez-CamposJL, Carrasco-HernandezL, Quintana-GallegoE, et al. Triple therapy for COPD: a crude analysis from a systematic review of the evidence. Ther Adv Respir Dis. 2019;13:1753466619885522. doi:10.1177/175346661988552231694491
   PubMed Web of Science ®Google Scholar
• LipsonDA, BarnacleH, BirkR, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–446. doi:10.1164/rccm.201703-0449OC28375647
   PubMed Web of Science ®Google Scholar
• SinghD, PapiA, CorradiM, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–973. doi:10.1016/S0140-6736(16)31354-X27598678
   PubMed Web of Science ®Google Scholar
• FergusonGT, RabeKF, MartinezFJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, Phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758. doi:10.1016/S2213-2600(18)30327-830232048
   PubMed Web of Science ®Google Scholar
• BremnerPR, BirkR, BrealeyN, IsmailaAS, ZhuCQ, LipsonDA. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study. Respir Res. 2018;19(1). doi:10.1186/s12931-018-0724-0
   PubMed Web of Science ®Google Scholar
• Garcia-RioF, Soler-CatalunaJJ, AlcazarB, ViejoJL, MiravitllesM. Requirements, strengths and weaknesses of inhaler devices for COPD patients from the expert prescribers’ point of view: results of the EPOCA Delphi consensus. COPD. 2017;14(6):573–580. doi:10.1080/15412555.2017.136512028891722
   PubMedGoogle Scholar
• MalerbaM, NardinM, SantiniG, MoresN, RadaeliA, MontuschiP. Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects. Ther Adv Respir Dis. 2018;12:1753466618760779. doi:10.1177/175346661876077929537340
   PubMed Web of Science ®Google Scholar
• SinghD, CorradiM, SpinolaM, et al. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide. Int J Chron Obstruct Pulmon Dis. 2017;12:2917–2928. doi:10.2147/COPD.S14682229062229
   PubMed Web of Science ®Google Scholar
• LalC, StrangeC. Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy. Int J Chron Obstruct Pulmon Dis. 2017;12:135–140. doi:10.2147/COPD.S11427328115838
   PubMed Web of Science ®Google Scholar
• IsmailaAS, BirkR, ShahD, et al. Once-daily triple therapy in patients with advanced COPD: healthcare resource utilization data and associated costs from the FULFIL trial. Adv Ther. 2017;34(9):2163–2172. doi:10.1007/s12325-017-0604-x28875459
   PubMed Web of Science ®Google Scholar
• JonesJ, HunterD. Consensus methods for medical and health services research. BMJ. 1995;311(7001):376–380. doi:10.1136/bmj.311.7001.3767640549
   PubMed Web of Science ®Google Scholar